.jpg?format=webp&width=780)
In India, the Drugs Technical Advisory Board (DTAB) seeks to reclassify nicotine replacement therapies (NRT) as prescription-only. Under the proposed move, NRT products like gums and patches will require authorization from medical practitioners, potentially limiting access for tobacco users seeking to quit. Advocates argue that NRT is safe and effective for smoking cessation, with a 50% higher success rate than quitting without it. Critics stress the importance of accessible NRT to combat India's 28.6% adult tobacco use rate.
Like
Save
Share